Misoprostol use for labor induction in developing countries: a prospective study in Guinea.
BACKGROUND
The purpose of this study was to assess the efficacy, side effects and cost of misoprostol regimens in various obstetrical situations frequently occurring in developing countries.


METHODS
One hundred and four parturient women with indications for labor induction received different regimens of misoprostol in the range of 50-800 microg according to their gestational age. Misoprostol was administered by the vaginal route, every 6h without exceeding four doses.


RESULTS
All indications for labor induction concerned women with a gestational age of more than 30 weeks, except in the intrauterine death cases. The mean overall duration of labor was 7.8 h (+/-4.6 h). The mean amount of misoprostol used was 226 microg (+/-196 microg). The difference in the mean labor duration between the four indications for induction was statistically significant (P<0.01). It was also significant for the mean total dose of misoprostol used. Total dose of misoprostol and Bishop score were inversely proportional. Two caesarean deliveries and two uterine ruptures were recorded, but no maternal deaths. The mean Apgar score was 8.0 (+/-1) at 1 min and 9.5 (+/-0.8) at 5 min. In our series, four fetal deaths occurred. The mean cost of misoprostol for labor induction was around US$ 1, with a range of 0.05-4.


CONCLUSIONS
The use of vaginal misoprostol appears to be relevant in developing countries in cases where labor induction is indicated. Nevertheless, the advantages of misoprostol (low cost, facility of storage) are counter-balanced by side-effects (C-section, uterine rupture) which can be harmful for the mother and also for the newborn.
Yolande
Hyjazi
H
Department of Obstetrics and Gynaecology, University Hospital, Donka, Guinea.
Namory
Keîta
K
Delphine
Fenieys
F
Mamadou Hady
Diallo
D
Mamadou Diouldé
Baldé
B
Daniel
Tolno
T
Patrick
Thonneau
T
D000282:Administration, Intravaginal; D000328:Adult; D003362:Cost-Benefit Analysis; D003906:Developing Countries; D004334:Drug Administration Schedule; D005260:Female; D016701:Guinea; D006801:Humans; D007751:Labor, Induced; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D010120:Oxytocics; D011247:Pregnancy; D011446:Prospective Studies
D010120:Oxytocics; D016595:Misoprostol